I hereby request the following samples for professional evaluation or clinical research carried out at the institutional level, and in doing so I understand the following:
- These samples of infant formula products have been provided under the provisions of Clause 7 (d) of the Marketing in Australia of Infant Formula: Manufacturers and Importers Agreement (MAIF Agreement): Manufacturers and importers of infant formula should not provide samples of infant formulas, or equipment or utensils for their preparation or use, to health care professionals except when necessary for the purpose of professional evaluation or clinical research carried out at the institutional level;
- Where the suitability of a product is being assessed for an individual infant, the professional evaluation should always include a follow-up appointment with the mother of the infant;
- The product samples of infant formula products should be kept out of public view;
- The samples are not to be resold or taken for personal use by the Healthcare Professional or other staff;
- Professional evaluation apples to one or all of the following situations:
- Analysis of products (ingredients, taste, nutritional profile);
- Trial preparation and mixing of infant formula products (includes preparation and mixing instructions to mothers);
- Investigative or development projects, using sound methodology and involving a number of infants;
- A thorough assessment of the suitability of a product for an individual infant, including acceptance of the product by the infant, when mothers have made the informed choice to use infant formula.
Bellamy’s Organic is a signatory to The Marketing in Australia of Infant Formulas: Manufacturers and Importers Agreement (MAIF Agreement). The MAIF Agreement is a voluntary, self-regulatory code which restricts signatories’ ability to promote and market breastmilk substitutes. The purpose of the agreement is to protect and encourage the promotion of breast milk as the optimal source of nutrients for all infants, and by ensuring the proper use of breast milk substitutes, when these are necessary, on the basis of adequate information and through appropriate marketing and distribution (WHO Code Article 1) (Clause 1 of the MAIF Agreement).